B-Cell Coinhibitory Targeting for Immune Suppression Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for autoimmune diseases and cancers are inadequate due to the lack of effective modulation of B-cell-mediated immunosuppression, particularly through regulatory B cells (Bregs), which are critical for maintaining immune tolerance and inflammation restraint.
Innovation Solution
Compositions and methods targeting coinhibitory molecules like TIGIT, PD-1, TIM-3, LAG-3, and CTLA-4 in B cells using multispecific binding agents, such as antibodies, to modulate immune suppression and treat diseases mediated by immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for autoimmune diseases and cancers, then general immune suppression is attempted, but B-cell-mediated immunosuppression cannot be effectively modulated
Solution Approach 1:
The patent applies local quality by making the immunosuppressive effect specific to B cells through the use of anti-CD19 antibodies. The composition selectively targets B cells expressing CD19 while leaving other immune cells unaffected, thereby achieving localized immunomodulation precisely where needed in the pathological context of B-cell-mediated autoimmune diseases and cancers
Solution Approach 2:
The patent uses anti-CD19 antibodies as an intermediary agent that specifically binds to CD19 on B cells. This intermediary enables selective targeting and modulation of B-cell-mediated immunosuppression without requiring direct intervention in broader immune pathways, thus improving reliability while maintaining adaptability
2Reliability
If coinhibitory molecules in B cells are targeted to treat autoimmune diseases, then immune suppression is reduced, but therapeutic specificity must be maintained
Solution Approach 1:
The patent segments the therapeutic approach by focusing specifically on B cells as the target population and using anti-CD19 antibodies to deliver the therapeutic effect selectively to this cell type. This segmentation simplifies the overall treatment strategy by isolating the target (B cells) from the broader immune system, thereby reducing therapeutic complexity while maintaining effectiveness
Solution Approach 2:
The patent employs parameter changes by utilizing the CD19 surface marker expression level and the binding characteristics of anti-CD19 antibodies to achieve selective targeting. By changing the parameter of antibody specificity for CD19, the therapy achieves high effectiveness without requiring complex multi-target mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances therapeutic strategies for autoimmune diseases and cancers by specifically targeting B cells, increasing or inhibiting the activity of these molecules to restore appropriate immune responses.
Implementation Method 1
The inhibitor comprises a multispecific binding agent comprising a moiety that binds and inhibits the activity of TIGIT, PD-1, TIM-3, LAG-3, or CTLA-4
Implementation Method 2
the moiety that binds a B-cell-specific cell-surface polypeptide marker comprises an antigen-binding domain of an antibody that specifically binds a B-cell-specific cell surface marker
Data Source
Figure 1A
Figure 1B
Figure 1C~1D
AI summary
The compositions and methods described herein are based, in part, on the discovery that regulatory B cells (Bregs) differentially express a specific set of coinhibitory molecules, including TIGIT, LAG-3, PD-1, CTLA4, and TIM-3. The data described herein indicate that TIGIT is required for both Bregmediated tolerance maintenance at the steady state, and inflammation restraint during autoimmune and inflammatory diseases. Accordingly, provided herein are compositions and methods targeting coinhibitory molecules, such as TIGIT, LAG-3, PD-1, CTLA4, and TIM-3, in B cells, as novel therapeutic strategies for modulating immune suppression and treating diseases mediated or impacted by immune suppression mechanisms, such as autoimmune diseases and cancers.